TPIDB > Principal Investigator
Principal Investigator
Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.
(在職)
Division of General Internal Medicine
Division of Thoracic Medicine
更新時間：2023-09-19
王金洲WANG, CHIN-CHOU
- Principal Investigator
- Clinical Trial Experience (year) 17 years 9 個月
-
ccwang52@cgmh.org.tw
Publication
33Publications
21
Chiu TH, Tung PH, Huang CH, Ju JS, Huang AC, Wang CC, et al. The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis. Sci Rep. 2022;12(1):4398.
22
Chang YC, Fang YT, Chen HC, Lin CY, Chang YP, Tsai YH, et al. The Survival of Septic Patients with Compensated Liver Cirrhosis Is Not Inferior to That of Septic Patients without Liver Cirrhosis: A Propensity Score Matching Analysis. J Clin Med. 2022;11(6).
23
Huang CH, Ju JS, Chiu TH, Huang AC, Tung PH, Wang CC, et al. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. Int J Cancer. 2022;150(4):626-35.
24
Ko HW, Chiu CT, Wang CL, Yang TY, Liu CY, Yu CT, et al. Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab. Cancers (Basel). 2022;14(14).
25
Kuo CS, Chiu TH, Tung PH, Huang CH, Ju JS, Huang AC, et al. Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers (Basel). 2022;14(2)
26
Lee SH, Lin YC, Chiu LC, Ju JS, Tung PH, Huang AC, et al. Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Ther Adv Med Oncol. 2022;14:17588359221113278.
27
Tsai KF, Cheng FJ, Huang WT, Kung CT, Lee CT, Cheng BC, et al. The associations between renal disease severity and exposure to organophosphate flame retardants in patients with chronic kidney disease. Environ Int. 2022;170:107573.
28
Wang CC, Lin WH, Ku SC, Shen WJ, Ta HDK, Anuraga G, et al. Circadian rhythm-related factors of PER and CRY family genes function as novel therapeutic targets and prognostic biomarkers in lung adenocarcinoma. Aging (Albany NY). 2022;14(22):9056-89.
29
Wang CC, Shen WJ, Anuraga G, Hsieh YH, Khoa Ta HD, Xuan DTM, et al. Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma. J Pers Med. 2022;13(1).
30
30. Wang CC, Shen WJ, Anuraga G, Khoa Ta HD, Xuan DTM, Chen ST, et al. Novel Potential Therapeutic Targets of PTPN Families for Lung Cancer. J Pers Med. 2022;12(12).
